Literature DB >> 16765178

Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma.

Morgan Rouprêt1, Vincent Hupertan, Olivier Traxer, Guillaume Loison, Emmanuel Chartier-Kastler, Pierre Conort, Marc-Olivier Bitker, Bernard Gattegno, François Richard, Olivier Cussenot.   

Abstract

OBJECTIVES: To compare the outcomes in patients who had undergone either open nephroureterectomy or conservative endoscopic surgery (ureteroscopic or percutaneous management) for upper urinary tract transitional cell carcinoma.
METHODS: We performed a retrospective review of the data for patients treated surgically for upper urinary tract transitional cell carcinoma from 1990 to 2004. The data included patient sex, age at diagnosis, mode of diagnosis, smoking history, history of bladder cancer, type of surgery, complications, and tumor site, size, stage, grade, recurrence, and progression. We also evaluated the recurrence and survival rates.
RESULTS: Data were analyzed for 97 patients. The median patient age was 68 years. Sixteen patients had a history of bladder tumor. The surgical procedure was open nephroureterectomy in 54 patients, ureteroscopy in 27, and percutaneous endoscopic ablation in 16. The tumor stage, grade, and site were independent prognostic factors for survival in a multivariate analysis (P <0.05). The 5-year disease-specific survival rate was 81.9% for low-grade tumors and 47.3% for high-grade tumors (P = 0.0001). A correlation (P = 0.002) was found between low-grade tumors and superficial tumors. In patients with low-grade tumors (n = 46), the 5-year disease-specific survival rate after nephroureterectomy, ureteroscopy, and percutaneous endoscopy was 84%, 80.7%, and 80%, respectively (P = 0.89); the corresponding 5-year tumor-free survival rates were 75.3%, 71.5%, and 72% (P = 0.78).
CONCLUSIONS: Conservative surgery can be recommended as an alternative to nephroureterectomy for low-grade or superficial upper urinary tract transitional cell carcinoma. For patients with high-grade or invasive tumors to be candidates for conservative surgery will require the development of additional prognostic factors (eg, molecular markers). These patients require long-term postoperative surveillance.

Entities:  

Mesh:

Year:  2006        PMID: 16765178     DOI: 10.1016/j.urology.2005.12.034

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  25 in total

1.  Correlation between surgical modality and clinicopathologic characteristics for ureteral transitional cell carcinoma.

Authors:  S Bing-bing; C Cheng; L Han-zhong; R Shi; H Zhong-ming; F Hua; W Jin; W Qing-hai; J Zhi-gang; F Yujiang
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

Review 2.  Lasers in percutaneous renal procedures.

Authors:  Nadya M Cinman; Sero Andonian; Arthur D Smith
Journal:  World J Urol       Date:  2009-06-02       Impact factor: 4.226

3.  Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.

Authors:  Michael Metcalfe; Gavin Wagenheim; Lianchun Xiao; John Papadopoulos; Neema Navai; John W Davis; Jose A Karam; Ashish M Kamat; Christopher G Wood; Colin P Dinney; Surena F Matin
Journal:  J Endourol       Date:  2017-07-21       Impact factor: 2.942

Review 4.  Role of lasers in urology.

Authors:  Stephan M Korn; Nicolai A Hübner; Christian Seitz; Shahrokh F Shariat; Harun Fajkovic
Journal:  Photochem Photobiol Sci       Date:  2019-02-13       Impact factor: 3.982

Review 5.  [Instillation therapies for urothelial carcinoma of the upper urinary tract].

Authors:  P Bosshard; G N Thalmann; B Roth
Journal:  Urologe A       Date:  2019-01       Impact factor: 0.639

6.  Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma.

Authors:  Jay Simhan; Marc C Smaldone; Brian L Egleston; Daniel Canter; Steven N Sterious; Anthony T Corcoran; Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

7.  Conservative treatment of upper urinary tract carcinoma: Long-term results.

Authors:  Andrea Orosa Andrada; Inés Laso García; Fernando Arias Fúnez; Francisco Donis Canet; Gemma Duque Ruiz; Victoria Gómez Dos Santos; Francisco Javier Burgos Revilla
Journal:  Can Urol Assoc J       Date:  2017-07-11       Impact factor: 1.862

Review 8.  [Endosopic organ-sparing treatment of urothelial tumors of the upper urinary tract: indications and results].

Authors:  M Hruza; C Stock; D Teber; J J Rassweiler
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

9.  Endoscopic management of upper tract transitional cell carcinoma.

Authors:  James A Forster; Victor Palit; Anthony J Browning; Chandra Shekhar Biyani
Journal:  Indian J Urol       Date:  2010-04

10.  Conservative nephron-sparing treatment of upper-tract tumors.

Authors:  Paul Smith; Juliette Mandel; Jay D Raman
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.